Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.

MLA

Mease, Philip J., et al. “Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.” Rheumatology and Therapy, vol. 9, no. 5, Oct. 2022, pp. 1361–75. EBSCOhost, https://doi.org/10.1007/s40744-022-00474-5.

APA

Mease, P. J., Kellner, H., Morita, A., Kivitz, A. J., Aslanyan, S., Padula, S. J., Topp, A. S., Eldred, A., Behrens, F., & Papp, K. A. (2022). Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial. Rheumatology and Therapy, 9(5), 1361–1375. https://doi.org/10.1007/s40744-022-00474-5

Chicago

Mease, Philip J, Herbert Kellner, Akimichi Morita, Alan J Kivitz, Stella Aslanyan, Steven J Padula, Andrew S Topp, Ann Eldred, Frank Behrens, and Kim A Papp. 2022. “Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.” Rheumatology and Therapy 9 (5): 1361–75. doi:10.1007/s40744-022-00474-5.